Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #7955
Ace Report Cover Metabolic Disorders

Denosumab reduces secondary fragility fracture risk in osteoporotic women

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

Climacteric. 2015 Jun 1:1-23

Contributing Authors: S Palacios L Kalouche-Khalil R Rizzoli C Zapalowski H Resc JD Adachi JC Gallagher RG Feldman DL Kendler A Wang RB Wagman S Adami

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


7808 osteoperotic women part of the FREEDOM study, were analyzed in this post-hoc analysis. The purpose of this study was to determine how efficacious denosumab (60mg for 36 months) was in preventing fragility fractures and secondary fragility fractures as compared to a placebo. Results indicated that prior fragility fracture was present in 45% of the population, and denosumab treatment significan...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.